WO2013182946A3 - Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs - Google Patents

Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs Download PDF

Info

Publication number
WO2013182946A3
WO2013182946A3 PCT/IB2013/054313 IB2013054313W WO2013182946A3 WO 2013182946 A3 WO2013182946 A3 WO 2013182946A3 IB 2013054313 W IB2013054313 W IB 2013054313W WO 2013182946 A3 WO2013182946 A3 WO 2013182946A3
Authority
WO
WIPO (PCT)
Prior art keywords
vilazodone
preparation
hydrobromide
polymorphs
crystalline form
Prior art date
Application number
PCT/IB2013/054313
Other languages
French (fr)
Other versions
WO2013182946A2 (en
Inventor
Nitin Maheshwari
Prasenjit Das
Bindu Srivastava
Hashim Nizar Poovanathil Nagoor Meeran
Mohan Prasad
Sudershan Kumar Arora
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2013182946A2 publication Critical patent/WO2013182946A2/en
Publication of WO2013182946A3 publication Critical patent/WO2013182946A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides vilazodone hydrobromide, its process of preparation, pharmaceutical composition, and method of use. The present invention further provides processes of preparation of vilazodone hydrochloride using vilazodone hydrobromide. The present invention further provides crystalline Form A, crystalline Form B and crystalline Form C of vilazodone free base along with their processes of preparation, pharmaceutical compositions, and method of use.
PCT/IB2013/054313 2012-06-06 2013-05-24 Process for the preparation of vilazodone hydrochloride WO2013182946A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1743/DEL/2012 2012-06-06
IN1743DE2012 2012-06-06

Publications (2)

Publication Number Publication Date
WO2013182946A2 WO2013182946A2 (en) 2013-12-12
WO2013182946A3 true WO2013182946A3 (en) 2014-03-13

Family

ID=48746614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/054313 WO2013182946A2 (en) 2012-06-06 2013-05-24 Process for the preparation of vilazodone hydrochloride

Country Status (1)

Country Link
WO (1) WO2013182946A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185209A1 (en) 2012-06-13 2013-12-19 Apotex Technologies Inc. Forms of vilazodone and processes for the preparation thereof
CA2884676A1 (en) 2012-09-12 2014-03-20 Apotex Pharmachem Inc. Processes for the preparation of 3-alkyl indoles
WO2015037010A1 (en) * 2013-09-13 2015-03-19 Symed Labs Limited Preparation of vilazodone hydrochloride crystalline form iv

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648767A1 (en) * 1993-09-30 1995-04-19 MERCK PATENT GmbH Piperdine and piperazine derivatives which affect the C.N.S.
EP0738722A1 (en) * 1995-04-20 1996-10-23 MERCK PATENT GmbH 5-Amino-benzofuran-2-carboxylic acid derivatives
CN102267985A (en) * 2011-06-15 2011-12-07 上海医药工业研究院 Preparation method for vilazodone and hydrochloride thereof
WO2013078361A1 (en) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
WO2013114338A1 (en) * 2012-02-01 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of vilazodone or its pharmaceutically acceptable salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76758C2 (en) 2001-06-19 2006-09-15 Мерк Патент Гмбх Polymorph forms of hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648767A1 (en) * 1993-09-30 1995-04-19 MERCK PATENT GmbH Piperdine and piperazine derivatives which affect the C.N.S.
EP0738722A1 (en) * 1995-04-20 1996-10-23 MERCK PATENT GmbH 5-Amino-benzofuran-2-carboxylic acid derivatives
CN102267985A (en) * 2011-06-15 2011-12-07 上海医药工业研究院 Preparation method for vilazodone and hydrochloride thereof
WO2013078361A1 (en) * 2011-11-23 2013-05-30 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
WO2013114338A1 (en) * 2012-02-01 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of vilazodone or its pharmaceutically acceptable salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEINRICH T ET AL: "Synthesis and Structure-Activity Relationship in a Class of Indolebutylpiperazines as Dual 5-HT1A Receptor Agonists and Serotonin Reuptake Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 47, no. 19, 1 January 2004 (2004-01-01), pages 4684 - 4692, XP002388367, ISSN: 0022-2623, DOI: 10.1021/JM040793Q *
SORBERA L A ET AL: "VILAZODONE HYDROCHLORIDE", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 26, no. 3, 1 January 2001 (2001-01-01), pages 247 - 252, XP009035003, ISSN: 0377-8282, DOI: 10.1358/DOF.2001.026.03.611242 *

Also Published As

Publication number Publication date
WO2013182946A2 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3312177A4 (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
HK1232229A1 (en) Novel compound of 4-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof 4-
EP3275867A4 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2013068850A3 (en) PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
EP3564224A3 (en) Crystalline form of vortioxetine hydrobromide as antidepressant drug
WO2013182946A3 (en) Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
EP2742946A4 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
EP3212640A4 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2014195977A3 (en) Novel polymorphs of vismodegib
EP3216791A4 (en) Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof
HK1210158A1 (en) Fluorine substituted cyclic amine compounds and preparation methods, pharmaceutical compositions, and uses thereof
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13734191

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13734191

Country of ref document: EP

Kind code of ref document: A2